These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 24723493)

  • 1. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
    Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
    Zent CS; Victoria Wang X; Ketterling RP; Hanson CA; Libby EN; Barrientos JC; Call TG; Chang JE; Liu JJ; Calvo AR; Lazarus HM; Rowe JM; Luger SM; Litzow MR; Tallman MS
    Am J Hematol; 2016 Mar; 91(3):308-12. PubMed ID: 26662208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
    Kempin S; Sun Z; Kay NE; Paietta EM; Mazza JJ; Ketterling RP; Frankfurt O; Claxton DF; Saltzman JN; Srkalovic G; Callander NS; Gross G; Tallman MS
    Acta Haematol; 2019; 142(4):224-232. PubMed ID: 31336367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody therapy for chronic lymphocytic leukemia.
    Christian BA; Lin TS
    Semin Hematol; 2008 Apr; 45(2):95-103. PubMed ID: 18381104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
    Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
    Lamanna N; Kalaycio M; Maslak P; Jurcic JG; Heaney M; Brentjens R; Zelenetz AD; Horgan D; Gencarelli A; Panageas KS; Scheinberg DA; Weiss MA
    J Clin Oncol; 2006 Apr; 24(10):1575-81. PubMed ID: 16520464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
    J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Brown JR; Messmer B; Werner L; Davids MS; Mikler E; Supko JG; Fisher DC; LaCasce AS; Armand P; Jacobsen E; Dalton V; Tesar B; Fernandes SM; McDonough S; Ritz J; Rassenti L; Kipps TJ; Neuberg D; Freedman AS
    Haematologica; 2013 Jun; 98(6):964-70. PubMed ID: 23645694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Zent CS; Wu W; Bowen DA; Hanson CA; Pettinger AM; Shanafelt TD; Kay NE; Leis JF; Call TG
    Leuk Lymphoma; 2013 Mar; 54(3):476-82. PubMed ID: 22853816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
    Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Zent CS; Call TG; Shanafelt TD; Tschumper RC; Jelinek DF; Bowen DA; Secreto CR; Laplant BR; Kabat BF; Kay NE
    Cancer; 2008 Oct; 113(8):2110-8. PubMed ID: 18759253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
    Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
    J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.